Novavax reported $108.16M in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Adma Biologics ADMA:US $ 15.89M 1.78M
Agenus AGEN:US $ 18.91M 39K
AstraZeneca AZN:LN 268.26B 35.48B
Astrazeneca AZN:US 3.27B 209M
Biocryst Pharmaceuticals BCRX:US $ 38.02M 3.74M
Dynavax Technologies DVAX:US $ 35.74M 4.27M
Genocea Biosciences GNCA:US $ 3.6M 473K
Geron GERN:US $ 7.44M 744K
GlaxoSmithKline GSK:LN 195.5B 18.5B
Mannkind MNKD:US $ 26.04M 5.35M
Merk MRK:US $ 2.42B 118M
Minerva Neurosciences NERV:US $ 2.83M 196.19K
Moderna Inc MRNA:US 211M 57M
Novartis NVS:US 3.59B 91M
Novavax NVAX:US $ 108.16M 12.17M
Pain Therapeutics PTIE:US $ 2.97M 54K
Peregrine Pharmaceuticals PPHM:US $ 6.38M 467K
Pfizer PFE:US $ 3.2B 506M
Sarepta Therapeutics SRPT:US $ 154.32M 82.48M
Tg Therapeutics TGTX:US $ 12.64M 7.97M